Immunosenescence of Human Natural Killer Cells

Journal of Innate Immunity - Tập 3 Số 4 - Trang 337-343 - 2011
Inmaculada Gayoso1, Beatriz Sánchez-Correa2, Carmen Campos1, Corona Alonso1, Alejandra Pera1, Javier G. Casado2, Sara Morgado2, Raquel Tarazona2, Rafael Solana1
1Department of Immunology, IMIBIC – Reina Sofia University Hospital, University of Cordoba, Cordoba, and
2Immunology Unit, Department of Physiology, University of Extremadura, Cáceres, Spain

Tóm tắt

Natural killer (NK) cells are a key component of innate immunity involved not only in the elimination of virus-infected or tumor cells but also in the regulation of the immune response by producing cytokines and chemokines that can activate other cellular components of innate and adaptive immunity. NK cell subsets are differentially affected by aging. Whereas CD56<sup>bright</sup> cells are decreased in healthy elderly individuals, the CD56<sup>dim</sup> subset is expanded. The expression of CD57, a marker of highly differentiated NK cells, is increased in the elderly; this supports the notion that a remodeling process of NK cell subsets occurs in aging with a gradual decrease in more immature CD56<sup>bright</sup> NK cells and an increase in highly differentiated CD56<sup>dim</sup> CD57+ NK cells. This NK cell redistribution can explain many of the phenotypic and functional changes in NK cells associated with healthy aging such as decreased proliferation and the maintenance of CD16-dependent cytotoxicity.

Từ khóa


Tài liệu tham khảo

10.1016%2Fj.critrevonc.2010.06.012

10.1111%2Fj.1749-6632.2009.05370.x

10.1016%2Fj.mad.2006.11.015

10.1016%2FS0264-410X%2899%2900489-2

10.1007%2Fs10522-006-9062-6

10.1038%2Fni1033

10.1016%2Fj.immuni.2006.05.003

10.1111%2Fj.1600-065X.2006.00462.x

10.1016%2FS1471-4906%2801%2902060-9

10.1007%2FBF02983234

10.1189%2Fjlb.0306191

10.1182%2Fblood-2009-08-238469

10.1182%2Fblood-2002-09-2876

10.1111%2Fj.1600-065X.2006.00458.x

10.1016%2Fj.smim.2006.03.003

10.1038%2Fnature03847

10.1038%2Fnri1863

10.1111%2Fj.1600-065X.2006.00460.x

10.1182%2Fblood-2010-04-281675

10.1182%2Fblood-2010-04-282301

10.1016%2FS0047-6374%2800%2900242-6

10.1016%2F0047-6374%2890%2990108-R

10.1016%2FS0531-5565%2898%2900076-X

10.1186%2F1742-4933-3-10

10.1111%2Fj.1474-9726.2010.00584.x

10.1111%2Fj.1365-2249.1990.tb05359.x

10.1006%2Fclin.1997.4401

10.1046%2Fj.1365-2249.2001.01571.x

10.1017%2FS0959259898008028

10.1016%2FS0531-5565%2801%2900162-0

10.1016%2Fj.exger.2004.08.005

10.1016%2F0167-5699%2895%2980064-6

10.1111%2Fj.1749-6632.1992.tb38717.x

10.1016%2F0047-6374%2894%2991592-X

10.1111%2Fj.1365-2567.2007.02573.x

10.1016%2FS0531-5565%2803%2900058-5

10.1016%2FS0047-6374%2803%2900015-0

10.1016%2FS0047-6374%2800%2900199-8

10.1182%2Fblood-2002-07-2103

10.1016%2FS0952-7915%2803%2900039-6

10.1016%2Fj.mad.2005.01.004

10.1016%2FS0531-5565%2899%2900008-X

10.1016%2FS0264-410X%2899%2900495-8

10.1016%2FS0047-6374%2897%2900173-5

10.1016%2Fj.humimm.2010.03.014

10.1182%2Fblood-2007-02-074468

10.1038%2Fni1190

10.1016%2Fj.semcancer.2006.07.005

10.1006%2Fcimm.1994.1112

10.1016%2F0047-6374%2896%2901772-1

10.1111%2Fj.0105-2896.2005.00273.x

10.1016%2FS0047-6374%2801%2900270-6

10.1002%2F1521-4141%28200206%2932%3A6%3C1524%3A%3AAID-IMMU1524%3E3.0.CO%3B2-E

10.1016%2FS0531-5565%2801%2900187-5